Overview
3D printing software and services provider's Q2 revenue falls 5.8%, missing analyst expectations
Belgium based company's Medical segment revenue grows 16.7% yr/yr, showing resilience
Adjusted EBITDA for Q2 beats analyst expectations, reflecting cost control efforts
Outlook
Materialise reduces 2025 revenue guidance to 265,000-280,000 kEUR
Company maintains 2025 Adjusted EBIT guidance of 6,000-10,000 kEUR
Materialise cites geopolitical and macroeconomic risks; forex fluctuations
Result Drivers
MEDICAL SEGMENT - Materialise Medical segment revenue increased 16.7%, demonstrating resilience despite broader revenue decline
COST CONTROL - Operational profitability improved due to structural and targeted cost control measures
EXCHANGE RATE IMPACT - Unfavorable exchange rate fluctuations significantly impacted quarterly financials, though net result remained positive
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | EUR 64.83 mln | EUR 67 mln (2 Analysts) |
Q2 EPS |
|
|
|
Q2 Net Income |
| EUR 199,000 |
|
Q2 Adjusted EBITDA | Beat | EUR 8.29 mln | EUR 6 mln (1 Analyst) |
Q2 Gross Profit |
| EUR 37.78 mln |
|
Q2 Operating Income |
| EUR 2.73 mln |
|
Q2 Pretax Profit |
| -EUR 322,000 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Materialise NV is $8.50, about 27.3% above its July 23 closing price of $6.18
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 31 three months ago
Press Release: ID:nBw50dCH8a